vs
Side-by-side financial comparison of Xiao-I Corp (AIXI) and CHAMPIONS ONCOLOGY, INC. (CSBR). Click either name above to swap in a different company.
CHAMPIONS ONCOLOGY, INC. is the larger business by last-quarter revenue ($15.0M vs $11.5M, roughly 1.3× Xiao-I Corp). CHAMPIONS ONCOLOGY, INC. runs the higher net margin — 1.8% vs -263.9%, a 265.7% gap on every dollar of revenue.
Xiao-i is a Chinese cognitive artificial intelligence enterprise founded in 2001.
Champions Oncology is an American technology company that develops mouse avatars. Called TumorGrafts, they are used to test a panel of chemotherapy regimens, targeted therapies and monoclonal antibodies to identify potential therapeutic options for cancer patients. The company was founded in 2007 by David Sidransky, M.D., a Johns Hopkins University oncologist.
AIXI vs CSBR — Head-to-Head
Income Statement — Q2 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $11.5M | $15.0M |
| Net Profit | $-30.4M | $268.0K |
| Gross Margin | 58.1% | 51.7% |
| Operating Margin | -254.9% | 1.2% |
| Net Margin | -263.9% | 1.8% |
| Revenue YoY | — | 11.5% |
| Net Profit YoY | — | -63.2% |
| EPS (diluted) | — | $0.02 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $15.0M | ||
| Q3 25 | — | $14.0M | ||
| Q2 25 | $11.5M | $12.4M | ||
| Q1 25 | — | $17.0M | ||
| Q4 24 | — | $13.5M | ||
| Q3 24 | — | $14.1M | ||
| Q2 24 | $33.0M | $14.0M | ||
| Q1 24 | — | $12.0M |
| Q4 25 | — | $268.0K | ||
| Q3 25 | — | $-436.0K | ||
| Q2 25 | $-30.4M | $-1.8M | ||
| Q1 25 | — | $4.5M | ||
| Q4 24 | — | $728.0K | ||
| Q3 24 | — | $1.3M | ||
| Q2 24 | $-15.5M | $-109.0K | ||
| Q1 24 | — | $-2.5M |
| Q4 25 | — | 51.7% | ||
| Q3 25 | — | 42.9% | ||
| Q2 25 | 58.1% | 41.1% | ||
| Q1 25 | — | 61.2% | ||
| Q4 24 | — | 44.9% | ||
| Q3 24 | — | 49.7% | ||
| Q2 24 | 64.5% | 48.2% | ||
| Q1 24 | — | 34.7% |
| Q4 25 | — | 1.2% | ||
| Q3 25 | — | -3.8% | ||
| Q2 25 | -254.9% | -16.2% | ||
| Q1 25 | — | 26.4% | ||
| Q4 24 | — | 5.4% | ||
| Q3 24 | — | 9.5% | ||
| Q2 24 | -45.0% | -1.9% | ||
| Q1 24 | — | -21.4% |
| Q4 25 | — | 1.8% | ||
| Q3 25 | — | -3.1% | ||
| Q2 25 | -263.9% | -14.9% | ||
| Q1 25 | — | 26.4% | ||
| Q4 24 | — | 5.4% | ||
| Q3 24 | — | 9.3% | ||
| Q2 24 | -47.2% | -0.8% | ||
| Q1 24 | — | -21.1% |
| Q4 25 | — | $0.02 | ||
| Q3 25 | — | $-0.03 | ||
| Q2 25 | — | $-0.12 | ||
| Q1 25 | — | $0.31 | ||
| Q4 24 | — | $0.05 | ||
| Q3 24 | — | $0.09 | ||
| Q2 24 | $-0.64 | $-0.01 | ||
| Q1 24 | — | $-0.19 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $5.0M | $8.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | — | $4.2M |
| Total Assets | $82.4M | $30.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $8.5M | ||
| Q3 25 | — | $10.3M | ||
| Q2 25 | $5.0M | $9.8M | ||
| Q1 25 | — | $3.2M | ||
| Q4 24 | — | $2.8M | ||
| Q3 24 | — | $2.9M | ||
| Q2 24 | $1.8M | $2.6M | ||
| Q1 24 | — | $4.5M |
| Q4 25 | — | $4.2M | ||
| Q3 25 | — | $3.5M | ||
| Q2 25 | — | $3.8M | ||
| Q1 25 | — | $5.5M | ||
| Q4 24 | — | $681.0K | ||
| Q3 24 | — | $-332.0K | ||
| Q2 24 | — | $-1.9M | ||
| Q1 24 | — | $-2.1M |
| Q4 25 | — | $30.2M | ||
| Q3 25 | — | $30.5M | ||
| Q2 25 | $82.4M | $32.3M | ||
| Q1 25 | — | $30.6M | ||
| Q4 24 | — | $25.2M | ||
| Q3 24 | — | $24.9M | ||
| Q2 24 | $87.6M | $26.1M | ||
| Q1 24 | — | $26.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-2.3M | $-1.7M |
| Free Cash FlowOCF − Capex | — | $-2.0M |
| FCF MarginFCF / Revenue | — | -13.1% |
| Capex IntensityCapex / Revenue | — | 1.6% |
| Cash ConversionOCF / Net Profit | — | -6.47× |
| TTM Free Cash FlowTrailing 4 quarters | — | $5.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-1.7M | ||
| Q3 25 | — | $600.0K | ||
| Q2 25 | $-2.3M | $6.9M | ||
| Q1 25 | — | $490.0K | ||
| Q4 24 | — | $-283.0K | ||
| Q3 24 | — | $311.0K | ||
| Q2 24 | — | $-1.8M | ||
| Q1 24 | — | $-919.0K |
| Q4 25 | — | $-2.0M | ||
| Q3 25 | — | $554.0K | ||
| Q2 25 | — | $6.6M | ||
| Q1 25 | — | $448.0K | ||
| Q4 24 | — | $-377.0K | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $-1.8M | ||
| Q1 24 | — | $-1.0M |
| Q4 25 | — | -13.1% | ||
| Q3 25 | — | 4.0% | ||
| Q2 25 | — | 53.5% | ||
| Q1 25 | — | 2.6% | ||
| Q4 24 | — | -2.8% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -13.0% | ||
| Q1 24 | — | -8.4% |
| Q4 25 | — | 1.6% | ||
| Q3 25 | — | 0.3% | ||
| Q2 25 | — | 2.0% | ||
| Q1 25 | — | 0.2% | ||
| Q4 24 | — | 0.7% | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | 0.0% | ||
| Q1 24 | — | 0.8% |
| Q4 25 | — | -6.47× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 0.11× | ||
| Q4 24 | — | -0.39× | ||
| Q3 24 | — | 0.24× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AIXI
Segment breakdown not available.
CSBR
| Pharmacology Services | $14.5M | 97% |
| Other | $520.0K | 3% |
